SAN DIEGO—(BUSINESS WIRE)—Jan. 5, 2016—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesto address unmet medical needs in central nervous system disorders,today announced that it intends to offer and sell, subject to market andother conditions, $300,000,000 of shares of its common stock in anunderwritten public offering. There can be no assurance as to whether orwhen the offering may be completed, or as to the actual size or terms ofthe offering.
BofA Merrill Lynch and J.P. Morgan Securities LLC are acting as thejoint book-running managers for the offering. ACADIA intends to grantthe underwriters a 30-day option to purchase an additional $45,000,000of shares of its common stock.
The shares of common stock described above are being offered by ACADIApursuant to a shelf registration statement filed by ACADIA with theSecurities and Exchange Commission (SEC) that became automaticallyeffective on March 3, 2014. A preliminary prospectus supplement relatedto the offering will be filed with the SEC and will be available on theSEC’s website located at http://www.sec.gov.Copies of the preliminary prospectus supplement and the accompanyingprospectus related to this offering, when available, may be obtainedfrom BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn:Prospectus Department, Email: dg.prospectus_requests@baml.com,or from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at866-803-9204.
This press release shall not constitute an offer to sell or thesolicitation of an offer to buy these securities, nor shall there be anysale of these securities in any state or other jurisdiction in whichsuch offer, solicitation or sale would be unlawful prior to theregistration or qualification under the securities laws of any suchstate or other jurisdiction.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA has a pipeline of productcandidates led by NUPLAZID™ (pimavanserin), for which we have submitteda New Drug Application (NDA) in Parkinson’s disease psychosis to the FDAand which has the potential to be the first drug approved in the UnitedStates for this condition. The FDA has classified the NUPLAZID NDA ashaving Priority Review status. Pimavanserin is also in Phase IIdevelopment for Alzheimer’s disease psychosis and has successfullycompleted a Phase II trial in schizophrenia. ACADIA also hasclinical-stage programs for glaucoma and, in collaboration withAllergan, Inc., for chronic pain.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include, but arenot limited to, statements related to the proposed offering of commonstock by ACADIA and the potential of NUPLAZID to be the first drugapproved in the United States for Parkinson’s disease psychosis. Thesestatements are only predictions based on current information andexpectations and involve a number of risks and uncertainties. Actualevents or results may differ materially from those projected in any ofsuch statements due to various factors, including market risks anduncertainties and the satisfaction of customary closing conditions foran offering of securities and the risks and uncertainties inherent indrug discovery, development, approval and commercialization. For adiscussion of these and other factors, please refer to ACADIA’s annualreport on Form 10-K for the year ended December 31, 2014 as well asACADIA’s subsequent filings with the Securities and Exchange Commission.You are cautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date hereof. This caution is madeunder the safe harbor provisions of the Private Securities LitigationReform Act of 1995. All forward-looking statements are qualified intheir entirety by this cautionary statement and ACADIA undertakes noobligation to revise or update this press release to reflect events orcircumstances after the date hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director ofInvestor Relations
(858) 558-2871